Bausch + Lomb Corporation – NYSE:BLCO
Bausch + Lomb stock price today
$14.979
-2.99
-16.64%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 11 hours
Bausch + Lomb stock price monthly change
+12.73%
month
Bausch + Lomb stock price quarterly change
+12.73%
quarter
Bausch + Lomb stock price yearly change
+9.17%
year
Bausch + Lomb key metrics
Market Cap | 6.20B |
Enterprise value | 7.90B |
P/E | 831.5 |
EV/Sales | 2.09 |
EV/EBITDA | 13.41 |
Price/Sales | 1.54 |
Price/Book | 0.82 |
PEG ratio | -8.59 |
EPS | -0.96 |
Revenue | 4.31B |
EBITDA | 508M |
Income | -337M |
Revenue Q/Q | 18.04% |
Revenue Y/Y | 13.22% |
Profit margin | 0.16% |
Oper. margin | 5.84% |
Gross margin | 59.69% |
EBIT margin | 5.84% |
EBITDA margin | 11.78% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBausch + Lomb stock price history
Bausch + Lomb stock forecast
Bausch + Lomb financial statements
Average Price Target
$22.43
Potential upside: 49.73%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 1.03B | -32M | -3.09% |
|---|---|---|---|
| Sep 2023 | 1.00B | -84M | -8.34% |
| Dec 2023 | 1.17B | -54M | -4.6% |
| Mar 2024 | 1.09B | -167M | -15.2% |
| 2024-02-21 | 0.17 | 0.24 |
|---|---|---|
| 2024-05-01 | 0.09 | 0.07 |
| Jun 2023 | 11315000000 | 4.28B | 37.87% |
|---|---|---|---|
| Sep 2023 | 13068000000 | 6.18B | 47.33% |
| Dec 2023 | 13442000000 | 6.52B | 48.52% |
| Mar 2024 | 13293000000 | 6.56B | 49.38% |
| Jun 2023 | -24M | -28M | 90M |
|---|---|---|---|
| Sep 2023 | 48M | -1.88B | 1.81B |
| Dec 2023 | 15M | -135M | 86M |
| Mar 2024 | 41M | -57M | 12M |
Bausch + Lomb alternative data
| Aug 2023 | 12,900 |
|---|---|
| Sep 2023 | 13,000 |
| Oct 2023 | 13,000 |
| Nov 2023 | 13,000 |
| Dec 2023 | 13,000 |
| Jan 2024 | 13,000 |
| Feb 2024 | 13,000 |
| Mar 2024 | 13,300 |
| Apr 2024 | 13,300 |
| May 2024 | 13,300 |
| Jun 2024 | 13,300 |
| Jul 2024 | 13,300 |
Bausch + Lomb other data
5.54%
-7.25%
of BLCO is owned by hedge funds
40
-45
19.38M
-25.36M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2024 | 32250 | 0 |
| Quarter | Transcript |
|---|---|
| Q2 2024 1 May 2024 | Q2 2024 Earnings Call Transcript |
| Q1 2024 1 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 21 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 1 Nov 2023 | Q3 2023 Earnings Call Transcript |
Bausch + Lomb Corporation: Spin-Off Ready To Fly Troubled Nest And Find Upside
Harrow: The Bull Thesis Is On Track, But Short-Term Challenges Loom
Hovering Around 52-Week Low, Bausch + Lomb May Be Poised For A Rebound
From Euphoria To Reality: Viatris' Tale Of Market Whirlwind
National Vision: Eyes Set Toward The Future
Bausch + Lomb: $2.5bn M&A Deal Shows It Hasn't Learned From Parent's Mistakes
National Vision Holdings: Keep An Eye On This One
Tracking Carl Icahn's Portfolio - Q4 2022 Update
Bausch Health: Full Bausch + Lomb Spin-Off Finally Seems Close
-
What's the price of Bausch + Lomb stock today?
One share of Bausch + Lomb stock can currently be purchased for approximately $14.98.
-
When is Bausch + Lomb's next earnings date?
Unfortunately, Bausch + Lomb's (BLCO) next earnings date is currently unknown.
-
Does Bausch + Lomb pay dividends?
No, Bausch + Lomb does not pay dividends.
-
How much money does Bausch + Lomb make?
Bausch + Lomb has a market capitalization of 6.20B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 10.03% to 4.15B US dollars. Bausch + Lomb made a loss 260M US dollars in net income (profit) last year or $0.07 on an earnings per share basis.
-
What is Bausch + Lomb's stock symbol?
Bausch + Lomb Corporation is traded on the NYSE under the ticker symbol "BLCO".
-
What is Bausch + Lomb's primary industry?
Company operates in the Healthcare sector and Medical - Instruments & Supplies industry.
-
How do i buy shares of Bausch + Lomb?
Shares of Bausch + Lomb can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Bausch + Lomb have?
As Jul 2024, Bausch + Lomb employs 13,300 workers.
-
When Bausch + Lomb went public?
Bausch + Lomb Corporation is publicly traded company for more then 3 years since IPO on 6 May 2022.
-
What is Bausch + Lomb's official website?
The official website for Bausch + Lomb is bausch.com.
-
Where are Bausch + Lomb's headquarters?
Bausch + Lomb is headquartered at 520 Applewood Crescent, Vaughan, ON.
-
How can i contact Bausch + Lomb?
Bausch + Lomb's mailing address is 520 Applewood Crescent, Vaughan, ON and company can be reached via phone at +90 56957700.
-
What is Bausch + Lomb stock forecast & price target?
Based on 7 Wall Street analysts` predicted price targets for Bausch + Lomb in the last 12 months, the avarage price target is $22.43. The average price target represents a 49.73% change from the last price of $14.98.
Bausch + Lomb company profile:
Bausch + Lomb Corporation
bausch.comExchange:
NYSE
Full time employees:
13,000
Industry:
Medical - Instruments & Supplies
Sector:
Healthcare
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
520 Applewood Crescent
Vaughan, ON L4K 4B4
Vaughan, ON L4K 4B4
CIK: 0001860742
ISIN: CA0717051076
CUSIP: 071705107
